Product Images Progesterone
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 10 images provide visual information about the product associated with Progesterone NDC 71335-0835 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - lbl713350835
This appears to be a medication package for 100mg progesterone capsules. It should be stored at room temperature between 20-25°C (68-77°F) and kept out of reach of children. The package includes 30 capsules, and the company name listed is USGP, a division of Procaps. The NDC number for this medication is 7133508351. No additional information is available.*
Structural Formula - pro0g 0006 01
Table 1 - pro0g 0006 02
Table 2 - pro0g 0006 03
Table 3 - pro0g 0006 04
The given text appears to be a table representing some sort of medical study. It mentions a treatment group with details of drugs and dosages administered, along with the number of patients in the study. The text also contains some medical terms such as "hyperplasia" and mentions a 3-year treatment duration. As the text is incomplete and lacks further details, it cannot be evaluated beyond this point and may not be useful.*
Figure 1 - pro0g 0006 05
This is a graph showing the duration of treatment (up to 36 months) of Ryperpas in a sample of patients. The y-axis represents the total number of patients remaining on medication, while the x-axis represents the duration of treatment in months. The graph shows a decreasing trend in the number of patients remaining on Ryperpas as the duration of treatment increases. The total number of patients in the sample varies at each time interval ranging from 25 to 312.*
Table 4 - pro0g 0006 06
Table 5 - pro0g 0006 07
This is not-available because the text seems to be a combination of incomplete words, garbled phrases, and non-English characters.*
Table 6 - pro0g 0006 08
This is a report of the adverse reactions reported in a 3-year placebo-controlled trial of Progesterone Capsules with Conjugated Estrogens in postmenopausal women. The report lists the percentage of patients who reported various side effects such as headaches, breast tenderness, depression, and urinary problems, among others.*
Table 7 - pro0g 0006 09
This is a table of adverse reactions in women who were taking either 400 mg/day progesterone capsules or a placebo. The trial was conducted in estrogen-primed postmenopausal women. The table shows the number of patients who reported adverse reactions and their percentages. The adverse reactions reported by patients taking the progesterone capsules included headache, bloating, cramping, back pain, musculoskeletal pain, irritability, breast pain, infection, and coughing. Patients who took placebo had similar adverse reactions but in fewer numbers.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
